ATE501125T1 - Verfahren zur herstellung des calciumsalzes von rosuvastatin - Google Patents

Verfahren zur herstellung des calciumsalzes von rosuvastatin

Info

Publication number: ATE501125T1
Authority: AT; Austria
Prior art keywords: rosuvastatin; producing; calcium salt; calcium; salt
Prior art date: 2002-08-13

Application number

AT03784274T

Other languages

English (en)

Inventor

John Horbury

Nigel Taylor

Original Assignee

Astrazeneca Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-13

Filing date

2003-08-07

Publication date

2011-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE501125(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-07 Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE501125T1 publication Critical patent/ATE501125T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03784274T 2002-08-13 2003-08-07 Verfahren zur herstellung des calciumsalzes von rosuvastatin ATE501125T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0218781.3A GB0218781D0 (en)	2002-08-13	2002-08-13	Chemical process
PCT/GB2003/003463 WO2004014872A1 (en)	2002-08-13	2003-08-07	Process for preparing the calcium salt of rosuvastatin

Publications (1)

Publication Number	Publication Date
ATE501125T1 true ATE501125T1 (de)	2011-03-15

Family

ID=9942204

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03784274T ATE501125T1 (de)	2002-08-13	2003-08-07	Verfahren zur herstellung des calciumsalzes von rosuvastatin

Country Status (30)

Country	Link
US (2)	US7511140B2 (de)
EP (1)	EP1539711B1 (de)
JP (1)	JP4588446B2 (de)
KR (1)	KR101325827B1 (de)
CN (1)	CN100361979C (de)
AR (1)	AR040868A1 (de)
AT (1)	ATE501125T1 (de)
AU (1)	AU2003251369B2 (de)
BR (1)	BR0313394A (de)
CA (1)	CA2495296C (de)
CY (1)	CY1112412T1 (de)
DE (1)	DE60336326D1 (de)
DK (1)	DK1539711T3 (de)
ES (1)	ES2361009T3 (de)
GB (1)	GB0218781D0 (de)
HK (1)	HK1082735A1 (de)
IL (1)	IL166626A (de)
IS (1)	IS7728A (de)
MX (1)	MXPA05001582A (de)
MY (1)	MY135301A (de)
NO (1)	NO329439B1 (de)
NZ (1)	NZ538070A (de)
PL (1)	PL375296A1 (de)
PT (1)	PT1539711E (de)
RU (1)	RU2326871C2 (de)
SI (1)	SI1539711T1 (de)
TW (1)	TWI316058B (de)
UA (1)	UA83805C2 (de)
WO (1)	WO2004014872A1 (de)
ZA (1)	ZA200500745B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6733780B1 (en)	1999-10-19	2004-05-11	Genzyme Corporation	Direct compression polymer tablet core
GB0003305D0 (en) *	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0011120D0 (en)	2000-05-09	2000-06-28	Avecia Ltd	Process
NL1015744C2 (nl)	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1301977C (zh)	2001-07-13	2007-02-28	阿斯特拉曾尼卡英国有限公司	氨基嘧啶化合物的制备方法
EP1323717A1 (de)	2001-12-27	2003-07-02	Dsm N.V.	Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
EP1375493A1 (de)	2002-06-17	2004-01-02	Dsm N.V.	Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
MXPA05006425A (es)	2002-12-16	2005-08-19	Astrazeneka Uk Ltd	Procedimiento para la preparacion de compuestos de pirimidina.
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
US7396927B2 (en) *	2003-08-28	2008-07-08	Teva Pharmaceutical Industries Ltd.	Process for preparation of rosuvastatin calcium
UY28501A1 (es) *	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en) *	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
WO2005051921A1 (en)	2003-11-24	2005-06-09	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
CA2546894C (en)	2003-12-02	2009-09-08	Teva Pharmaceutical Industries Ltd.	Reference standard for characterization of rosuvastatin
WO2005077917A1 (en) *	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Amorphous salts of rosuvastatin
US7241800B2 (en)	2004-03-17	2007-07-10	Mai De Ltd.	Anhydrous amorphous form of fluvastatin sodium
US7179916B2 (en)	2004-07-13	2007-02-20	Teva Pharmaceutical Industries Ltd.	Process for the preparation of rosuvastatin
US20080234302A1 (en) *	2004-09-27	2008-09-25	Mohammad Rafeeq	Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
US7985418B2 (en) *	2004-11-01	2011-07-26	Genzyme Corporation	Aliphatic amine polymer salts for tableting
CN101098859B (zh)	2004-12-23	2013-03-06	浙江海正药业股份有限公司	嘧啶酮类化合物及其制备和用途
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
EP1844021A1 (de) *	2005-01-31	2007-10-17	Ciba Specialty Chemicals Holding Inc.	Kristalline formen eines rosuvastatin-calciumsalzes
US7612203B2 (en)	2005-02-22	2009-11-03	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
ES2564807T5 (es)	2005-06-24	2019-02-26	Lek Pharmaceuticals	Proceso para preparación de rosuvastatina de calcio amorfa pura
AU2006261087B2 (en) *	2005-06-24	2010-09-30	Lek Pharmaceuticals D.D.	Process for preparing amorphous rosuvastatin calcium free of impurities
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
CA2617805A1 (en) *	2005-08-04	2007-02-15	Transform Pharmaceuticals, Inc.	Novel formulations comprising fenofibrate and a statin, and related methods of treatment
JP2008515931A (ja)	2005-08-16	2008-05-15	テバファーマシューティカルインダストリーズリミティド	結晶形ロスバスタチン中間体
JP2008513520A (ja)	2005-08-16	2008-05-01	テバファーマシューティカルインダストリーズリミティド	低塩分を伴うロスバスタチンカルシウム
CA2622693C (en)	2005-09-15	2015-05-05	Genzyme Corporation	Sachet formulation for amine polymers
SI2024341T1 (sl)	2006-05-03	2016-04-29	Msn Laboratories Private Limited	Novi postopek za statine in njihove farmacevtsko sprejemljive soli
US8404841B2 (en)	2006-10-09	2013-03-26	Msn Laboratories Limited	Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en)	2006-10-31	2012-11-27	Aurobindo Pharma Ltd	Process for preparing rosuvastatin calcium
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process
US8212034B2 (en)	2006-12-13	2012-07-03	Aurobindo Pharma Ltd.	Process for preparing rosuvastatin calcium
EP2125754B1 (de)	2007-02-08	2012-04-11	Aurobindo Pharma Limited	Verfahren zur herstellung von rosuvastatin-calcium
US20090069563A1 (en) *	2007-07-12	2009-03-12	Valerie Niddam-Hildesheim	Rosuvastatin intermediates and their preparation
HU230637B1 (hu) *	2007-10-12	2017-05-29	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Eljárás rosuvastatin intermedierek előállítására
HU230981B1 (hu) *	2007-10-12	2019-08-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Eljárás rosuvastatin só előállítására
CA2725052C (en)	2008-05-27	2014-09-16	Changzhou Pharmaceutical Factory Co., Ltd.	Preparation method of rosuvastatin calcium and its intermediates
WO2010035284A2 (en) *	2008-09-26	2010-04-01	Matrix Laboratories Ltd	An improved process for the preparation of rosuvastatin calcium
EP2350025A1 (de) *	2008-09-30	2011-08-03	Aurobindo Pharma Limited	Verbessertes verfahren zur herstellung von pyrimdinpropenaldehyd
CA2749727A1 (en)	2009-01-15	2010-07-22	Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag	Process for the preparation of rosuvastatin salts
US8487105B2 (en)	2009-01-19	2013-07-16	Msn Laboratories Limited	Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
WO2011086584A2 (en)	2010-01-18	2011-07-21	Msn Laboratories Limited	Improved process for the preparation of amide intermediates and their use thereof
AU2011243948B2 (en)	2010-04-23	2014-07-17	Sun Pharmaceutical Industries Limited	Novel intermediates for the preparation of HMG-CoA reductase inhibitors
HU230987B1 (hu)	2010-11-29	2019-08-28	Egis Gyógyszergyár Nyrt.	Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN105377817A (zh) *	2013-03-29	2016-03-02	中化帝斯曼制药有限公司荷兰公司	匹伐他汀和罗素伐他汀的胺盐
TWM477638U (zh) *	2013-12-12	2014-05-01	三緯國際立體列印科技股份有限公司	加熱平台與立體列印裝置
CN110198705A (zh)	2017-01-23	2019-09-03	同和药品株式会社	包含hmg-coa还原酶抑制剂和氯吡格雷的复合制剂
BR112021023782A2 (pt)	2019-05-27	2022-01-11	Immatics Us Inc	Vetores, métodos de preparação de células t para imunoterapia, populações de células t expandidas e métodos para tratar de um paciente com câncer e para elicitar uma resposta imune
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
SI26268A (sl)	2021-11-18	2023-05-31	Zupet Rok	Postopek za pripravo hidratirane oblike perindopril l-arginina

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US663641A (en) *	1900-10-11	1900-12-11	Charles A Ruebekam	Burial-casket.
US4645858A (en)	1982-03-22	1987-02-24	G. D. Searle & Co.	Pentanedioic acid derivatives
DE3741509A1 (de)	1987-12-08	1989-06-22	Hoechst Ag	Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
KR900701778A (ko)	1988-10-06	1990-12-04	예안 크라머, 한스 루돌프 하우스	피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물
US5026698A (en)	1988-11-02	1991-06-25	Nissan Chemical Industries, Ltd.	Thienopyridine type mevalonolactones
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
US5278313A (en)	1992-03-27	1994-01-11	E. R. Squibb & Sons, Inc.	Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DE59307409D1 (de)	1992-07-02	1997-10-30	Hoechst Ag	Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
IL128862A (en)	1995-07-17	2007-12-03	Warner Lambert Co	[R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
US6278001B1 (en)	1995-11-28	2001-08-21	L'oréal	Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr)	1995-11-28	1997-12-26	Oreal	Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
PT907639E (pt)	1996-06-24	2003-06-30	Novartis Ag	Compostos polimorficos
CN1226296C (zh)	1998-12-10	2005-11-09	钟渊化学工业株式会社	制备辛伐他汀的方法
GB9900339D0 (en) *	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
CN1164577C (zh) *	1999-07-13	2004-09-01	隆萨股份公司	2-氨基-4-(4-氟苯基)-6-烷基嘧啶-5-羧酸酯的制备方法
WO2001022962A1 (en)	1999-09-30	2001-04-05	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
CZ20021642A3 (cs)	1999-11-17	2003-05-14	Teva Pharmaceutical Industries Ltd.	Polymorfní formy atorvastatinu vápenatého
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en) *	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
AU2000254249A1 (en)	2000-03-28	2001-10-08	Biocon India Limited	Synthesis of (r-(r,r))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) *	2000-05-09	2000-06-28	Avecia Ltd	Process
GB0011163D0 (en) *	2000-05-10	2000-06-28	Astrazeneca Ab	Chemical compound
NL1015744C2 (nl)	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
JP3737801B2 (ja)	2000-10-05	2006-01-25	テバジョジセルジャールレースベニュタールシャシャーグ	プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
US6777552B2 (en)	2001-08-16	2004-08-17	Teva Pharmaceutical Industries, Ltd.	Processes for preparing calcium salt forms of statins
IL155890A0 (en)	2000-11-16	2003-12-23	Teva Pharma	HYDROLYSIS OF [R(R,R)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl)	2001-03-09	2002-09-10	Synthon Bv	Een lactonisatie proces.
IN190564B (de)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
CZ20033329A3 (cs)	2001-06-06	2004-11-10	Bristol-Myers Squibb Company	Způsob přípravy chirálních sulfondiolů a dihydroxykyselin inhibitorů HMG CoA reduktázy
CN1301977C (zh) *	2001-07-13	2007-02-28	阿斯特拉曾尼卡英国有限公司	氨基嘧啶化合物的制备方法
IL160077A0 (en)	2001-08-16	2004-06-20	Teva Pharma	Processes for preparing calcium salt forms of statins
CN1545502A (zh)	2001-08-22	2004-11-10	��⻯ѧƷ�ع��޹�˾	吲哚衍生物的制备方法
CA2459926A1 (en)	2001-09-24	2003-04-03	Merck & Co., Inc.	Screening and selection methods for statin drug combinations
EP1323717A1 (de) *	2001-12-27	2003-07-02	Dsm N.V.	Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
KR100511533B1 (ko)	2002-04-09	2005-08-31	임광민	키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AU2003228010A1 (en)	2002-05-21	2003-12-02	Ranbaxy Laboratories Limited	Process for the preparation of rosuvastatin
EP1375493A1 (de)	2002-06-17	2004-01-02	Dsm N.V.	Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en) *	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
HUP0500851A3 (en)	2002-12-10	2008-02-28	Ranbaxy Lab Ltd	Process for the preparation of rosuvastatin
MXPA05006425A (es) *	2002-12-16	2005-08-19	Astrazeneka Uk Ltd	Procedimiento para la preparacion de compuestos de pirimidina.
US8367848B2 (en)	2003-04-11	2013-02-05	Lek Pharmaceuticals D.D.	Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en)	2003-05-21	2004-12-02	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) *	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
AU2003247327A1 (en)	2003-07-15	2005-01-28	Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S.	Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
US7396927B2 (en)	2003-08-28	2008-07-08	Teva Pharmaceutical Industries Ltd.	Process for preparation of rosuvastatin calcium
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en)	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
WO2005040134A1 (en)	2003-10-22	2005-05-06	Ranbaxy Laboratories Limited	Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
DE10352659B4 (de)	2003-11-11	2007-09-13	Ratiopharm Gmbh	Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
US7028631B2 (en) *	2003-11-24	2006-04-18	The Boeing Company	Gliding submersible transport system
WO2005051921A1 (en)	2003-11-24	2005-06-09	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
CA2546894C (en)	2003-12-02	2009-09-08	Teva Pharmaceutical Industries Ltd.	Reference standard for characterization of rosuvastatin
WO2005054207A1 (en)	2003-12-04	2005-06-16	Glenmark Pharmaceuticals Limited	Process for the preparation of pyrimidine derivatives
US20050159615A1 (en)	2003-12-24	2005-07-21	Entire Interest.	Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs)	2004-01-16	2005-08-17	Zentiva, A.S.	Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en)	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Amorphous salts of rosuvastatin
EP1709008A1 (de)	2004-01-19	2006-10-11	Ranbaxy Laboratories Limited	Salze von hmg-coa-reduktase-inhibitoren und deren verwendung
US7241800B2 (en)	2004-03-17	2007-07-10	Mai De Ltd.	Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en)	2004-03-26	2004-04-28	Avecia Ltd	Process and compounds
US7161004B2 (en)	2004-06-21	2007-01-09	Dr. Reddy's Laboratories Limited	Processes to produce intermediates for rosuvastatin
US7179916B2 (en)	2004-07-13	2007-02-20	Teva Pharmaceutical Industries Ltd.	Process for the preparation of rosuvastatin
US20080234302A1 (en)	2004-09-27	2008-09-25	Mohammad Rafeeq	Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
GB0428328D0 (en) *	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
EP1844021A1 (de)	2005-01-31	2007-10-17	Ciba Specialty Chemicals Holding Inc.	Kristalline formen eines rosuvastatin-calciumsalzes
CA2498978A1 (en)	2005-02-28	2006-08-28	Apotex Pharmachem Inc.	An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process

2002
- 2002-08-13 GB GBGB0218781.3A patent/GB0218781D0/en not_active Ceased
2003
- 2003-07-08 UA UAA200500711A patent/UA83805C2/uk unknown
- 2003-08-07 AT AT03784274T patent/ATE501125T1/de active
- 2003-08-07 SI SI200331993T patent/SI1539711T1/sl unknown
- 2003-08-07 TW TW092121663A patent/TWI316058B/zh not_active IP Right Cessation
- 2003-08-07 DK DK03784274.7T patent/DK1539711T3/da active
- 2003-08-07 BR BR0313394-0A patent/BR0313394A/pt not_active IP Right Cessation
- 2003-08-07 JP JP2004527041A patent/JP4588446B2/ja not_active Expired - Lifetime
- 2003-08-07 RU RU2005102391/04A patent/RU2326871C2/ru active
- 2003-08-07 NZ NZ538070A patent/NZ538070A/en not_active IP Right Cessation
- 2003-08-07 ES ES03784274T patent/ES2361009T3/es not_active Expired - Lifetime
- 2003-08-07 AU AU2003251369A patent/AU2003251369B2/en not_active Expired
- 2003-08-07 KR KR1020057002408A patent/KR101325827B1/ko active IP Right Grant
- 2003-08-07 DE DE60336326T patent/DE60336326D1/de not_active Expired - Lifetime
- 2003-08-07 US US10/524,235 patent/US7511140B2/en not_active Expired - Lifetime
- 2003-08-07 MX MXPA05001582A patent/MXPA05001582A/es active IP Right Grant
- 2003-08-07 CN CNB038239949A patent/CN100361979C/zh not_active Expired - Lifetime
- 2003-08-07 PT PT03784274T patent/PT1539711E/pt unknown
- 2003-08-07 EP EP03784274A patent/EP1539711B1/de not_active Revoked
- 2003-08-07 PL PL03375296A patent/PL375296A1/xx unknown
- 2003-08-07 CA CA2495296A patent/CA2495296C/en not_active Expired - Fee Related
- 2003-08-07 WO PCT/GB2003/003463 patent/WO2004014872A1/en active Application Filing
- 2003-08-11 MY MYPI20033048A patent/MY135301A/en unknown
- 2003-08-13 AR AR20030102929A patent/AR040868A1/es unknown
2005
- 2005-01-31 NO NO20050542A patent/NO329439B1/no not_active IP Right Cessation
- 2005-02-01 IL IL166626A patent/IL166626A/en unknown
- 2005-03-08 IS IS7728A patent/IS7728A/is unknown
2006
- 2006-01-10 ZA ZA200500745A patent/ZA200500745B/en unknown
- 2006-02-27 HK HK06102591A patent/HK1082735A1/xx not_active IP Right Cessation
2009
- 2009-02-13 US US12/371,359 patent/US7842807B2/en not_active Expired - Lifetime
2011
- 2011-05-09 CY CY20111100442T patent/CY1112412T1/el unknown

Also Published As

Publication number	Publication date
TW200404786A (en)	2004-04-01
IL166626A (en)	2011-09-27
CY1112412T1 (el)	2015-12-09
EP1539711B1 (de)	2011-03-09
NO20050542L (no)	2005-02-28
ES2361009T3 (es)	2011-06-13
KR20050036968A (ko)	2005-04-20
KR101325827B1 (ko)	2013-11-05
JP2006500347A (ja)	2006-01-05
US20060116391A1 (en)	2006-06-01
US7842807B2 (en)	2010-11-30
WO2004014872A1 (en)	2004-02-19
US20090286819A1 (en)	2009-11-19
AU2003251369A1 (en)	2004-02-25
IS7728A (is)	2005-03-08
CA2495296C (en)	2011-05-03
PT1539711E (pt)	2011-05-03
EP1539711A1 (de)	2005-06-15
AR040868A1 (es)	2005-04-20
DK1539711T3 (da)	2011-05-30
NZ538070A (en)	2006-08-31
AU2003251369B2 (en)	2007-02-01
TWI316058B (en)	2009-10-21
DE60336326D1 (de)	2011-04-21
CA2495296A1 (en)	2004-02-19
RU2005102391A (ru)	2005-10-10
HK1082735A1 (en)	2006-06-16
NO329439B1 (no)	2010-10-18
SI1539711T1 (sl)	2011-06-30
PL375296A1 (en)	2005-11-28
IL166626A0 (en)	2006-01-15
CN100361979C (zh)	2008-01-16
US7511140B2 (en)	2009-03-31
JP4588446B2 (ja)	2010-12-01
RU2326871C2 (ru)	2008-06-20
MY135301A (en)	2008-03-31
CN1688551A (zh)	2005-10-26
GB0218781D0 (en)	2002-09-18
UA83805C2 (uk)	2008-08-26
ZA200500745B (en)	2006-03-29
MXPA05001582A (es)	2005-04-25
BR0313394A (pt)	2005-06-21

Publication	Publication Date	Title
ATE501125T1 (de)	2011-03-15	Verfahren zur herstellung des calciumsalzes von rosuvastatin
DE602004026576D1 (de)	2010-05-27	Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
DE60323192D1 (de)	2008-10-09	Verfahren zur Herstellung von Hydroxyalkylstärkederivaten
DE60128723D1 (de)	2007-07-12	Verfahren zur herstellung von bio-resorbierbaren implantaten
DE502004001613D1 (de)	2006-11-09	Verfahren zur herstellung von polyamiden
DE60330341D1 (de)	2010-01-14	Verfahren zur herstellung von wabenstrukturen
DE60302682D1 (de)	2006-01-19	Verfahren zur Herstellung von Nanopartikeln
DE60225539D1 (de)	2008-04-24	Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE60330050D1 (de)	2009-12-24	Verfahren zur herstellung von pyrimidinverbindungen
DE60204334D1 (de)	2005-06-30	Verfahren zur herstellung von repaglinide
DE50311721D1 (de)	2009-09-03	Verfahren zur Herstellung von Aryl-aminopropanolen
DE60234275D1 (de)	2009-12-17	Verfahren zur herstellung von diglyceriden
DE50303611D1 (de)	2006-07-06	Verfahren zur herstellung von polyisobuten
ATE424892T1 (de)	2009-03-15	Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE60113157T2 (de)	2006-06-14	Verbessertes verfahren zur herstellung von simvastatin
DE60322356D1 (de)	2008-09-04	Verfahren zur herstellung von 2-aminoindanderivaten
DE60309805D1 (de)	2007-01-04	Kontinuierliches Verfahren zur Herstellung von 3-Methylthiopropanal
DE602004001646D1 (de)	2006-09-07	Verfahren zur Herstellung von Pyran
DE602004005239D1 (de)	2007-04-19	Verfahren zur herstellung von tubulininhibitoren
DE60301444D1 (de)	2005-10-06	Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen
DE60302979D1 (de)	2006-02-02	Verfahren zur Herstellung von Epsilon-Caprolactone
DE602004018447D1 (de)	2009-01-29	Verfahren zur Herstellung von Alkylbenzaldehyden
DE60322872D1 (de)	2008-09-25	Verfahren zur herstellung von säuresalzen von gemifloxacin
DE60330749D1 (de)	2010-02-11	Verfahren zur herstellung von 7-alpha-methylsteroide
DE60324881D1 (de)	2009-01-08	Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen

Legal Events

Date	Code	Title	Description
2011-10-15	UEP	Publication of translation of european patent specification	Ref document number: 1539711 Country of ref document: EP

Date

Code

Title

Description

2011-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1539711

Country of ref document: EP